首页> 美国卫生研究院文献>Blood >Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation
【2h】

Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation

机译:腹膜内施用活化蛋白C可防止术后粘连带形成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Postsurgical peritoneal adhesion bands are the most important causes of intestinal obstruction, pelvic pain, and female infertility. In this study, we used a mouse model of adhesion and compared the protective effect of activated protein C (APC) to that of the Food and Drug Administration–approved antiadhesion agent, sodium hyaluronate/carboxymethylcellulose (Seprafilm) by intraperitoneal administration of either APC or Seprafilm to experimental animals. Pathological adhesion bands were graded on day 7, and peritoneal fluid concentrations of tissue plasminogen activator (tPA), d-dimer, thrombin–antithrombin complex, and cytokines (IL-1β, IL-6, interferon-γ, tumor necrosis factor-α, transforming growth factor-β1) were evaluated. Inflammation scores were also measured based on histologic data obtained from peritoneal tissues. Relative to Seprafilm, intraperitoneal administration of human APC led to significantly higher reduction of postsurgical adhesion bands. Moreover, a markedly lower inflammation score was obtained in the adhesive tissues of the APC-treated group, which correlated with significantly reduced peritoneal concentrations of proinflammatory cytokines and an elevated tPA level. Further studies using variants of human APC with or without protease-activated receptor 1 (PAR1) signaling function and mutant mice deficient for either endothelial protein C receptor (EPCR) or PAR1 revealed that the EPCR-dependent signaling activity of APC is primarily responsible for its protective activity in this model. These results suggest APC has therapeutic potential for preventing postsurgical adhesion bands.
机译:手术后腹膜粘连带是肠梗阻,骨盆疼痛和女性不育的最重要原因。在这项研究中,我们使用了小鼠黏附模型,并比较了通过腹膜内施用APC或FDA批准的活化蛋白C(APC)与食品和药物管理局批准的抗黏附剂透明质酸钠/羧甲基纤维素钠(Seprafilm)的保护作用。 Seprafilm用于实验动物。病理粘附带在第7天进行分级,组织纤溶酶原激活物(tPA),d-二聚体,凝血酶-抗凝血酶复合物和细胞因子(IL-1β,IL-6,干扰素-γ,肿瘤坏死因子-α)的腹膜液浓度,评价转化生长因子-β1)。还基于从腹膜组织获得的组织学数据来测量炎症评分。相对于Seprafilm,腹膜内施用人APC可显着提高术后粘连带的减少。而且,在APC治疗组的粘着组织中获得了明显更低的炎症评分,这与明显降低的腹膜促炎细胞因子浓度和升高的tPA水平相关。使用具有或不具有蛋白酶激活受体1(PAR1)信号传导功能的人APC变体以及缺乏内皮蛋白C受体(EPCR)或PAR1的突变小鼠进行的进一步研究表明,APC依赖EPCR的信号传导活性主要是由其引起的该模型中的保护性活动。这些结果表明,APC具有预防术后粘连的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号